Galimedix, Inc. | WebDisclosure

Basculer en Français

8769	Companies
157329	Keywords
92871	Articles
84793	Press releases

Home
Companies
Galimedix, Inc.

BRIEF

published on 05/21/2025 at 14:05, 1 month 22 days ago

Le GAL-201 de Galimedix s'avère prometteur dans le traitement de la maladie d'Alzheimer

GAL-201 Neuroinflammation Traitement De La Maladie D'Alzheimer Bêta-amyloïde Dommages Synaptiques
BRIEF

published on 05/21/2025 at 14:05, 1 month 22 days ago

Galimedix's GAL-201 Shows Promise in Alzheimer's Treatment

GAL-201 Neuroinflammation Alzheimer’s Treatment Amyloid-beta Synaptic Damage
PRESS RELEASE

published on 05/21/2025 at 14:00, 1 month 22 days ago

Galimedix Therapeutics publishes new data in peer-reviewed International Journal of Molecular Sciences demonstrating disease-modifying capability of GAL-201 in Alzheimer’s disease
Galimedix Therapeutics publishes new data in peer-reviewed International Journal of Molecular Sciences demonstrating disease-modifying capability of GAL-201 in Alzheimer’s disease

GAL-201 Galimedix Therapeutics Alzheimer’s Disease International Journal Of Molecular Sciences Neuroprotective Therapy
BRIEF

published on 05/06/2025 at 14:05, 2 months 6 days ago

Galimedix Therapeutics Completes Phase 1 Study with GAL-101

Alzheimer's Disease Galimedix Therapeutics GAL-101 Phase 1 Study AMD
BRIEF

published on 05/06/2025 at 14:05, 2 months 6 days ago

Galimedix Therapeutics achève l'étude de phase 1 avec GAL-101

Maladie D'Alzheimer Galimedix Therapeutics Étude De Phase 1 GAL-101 DMLA
PRESS RELEASE

published on 05/06/2025 at 14:00, 2 months 6 days ago

Galimedix Therapeutics completes single ascending dose part of Phase 1 study with oral small molecule, GAL-101, an amyloid beta aggregation modulator
Galimedix Therapeutics completes single ascending dose of Phase 1 study with oral small molecule GAL-101 targeting amyloid beta aggregation modulator, supporting oral administration route. Next study arms and indications revealed

Galimedix Therapeutics GAL-101 Oral Administration Phase 1 Study Amyloid Beta
BRIEF

published on 04/01/2025 at 09:05, 3 months 11 days ago

Galimedix publie des données prometteuses pour le traitement de la maladie d'Alzheimer

GAL-201 Maladie D'Alzheimer Galimedix Therapeutics Neuroinflammation Agrégation De L'amyloïde-β
BRIEF

published on 04/01/2025 at 09:05, 3 months 11 days ago

Galimedix Reports Promising Data for Alzheimer's Treatment

Alzheimer's Disease GAL-201 Galimedix Therapeutics Neuroinflammation Amyloid-β Aggregation
PRESS RELEASE

published on 04/01/2025 at 09:00, 3 months 11 days ago

Galimedix Therapeutics presents further scientific data showing disease-modifying potential of oral GAL-201 in Alzheimer’s disease as well as beneficial effects on synaptic function and neuroimmunomod
Galimedix Therapeutics presents new preclinical data on GAL-201 at AD/PD 2025, showing promise in Alzheimer’s disease treatment by targeting misfolded Aβ monomers and reducing Aβ plaques with anti-inflammatory effects

Alzheimer's Disease Preclinical Data GAL-201 Galimedix Therapeutics Neuroinflammation
BRIEF

published on 03/24/2025 at 15:12, 3 months 18 days ago

Galimedix Therapeutics to Present Promising Preclinical Alzheimer’s Treatment

Preclinical Data Galimedix Therapeutics Neuroprotection Alzheimer's Treatment Amyloid-beta

Accesswire

Published on 07/12/2025 at 02:40, 11 hours 32 minutes ago

Gold Mountain Mining Corp. Obtains Additional Funding Under Secured Convertible Debenture
Published on 07/12/2025 at 02:00, 12 hours 12 minutes ago

Battery X Metals Engages U.S. Investment Bank to Support Strategic Path Toward Potential United States National Securities Exchange Listing Aligned with U.S. Growth Initiatives
Published on 07/12/2025 at 00:00, 14 hours 12 minutes ago

BioNxt Solutions Announces Convertible Debenture Unit Private Placement
Published on 07/12/2025 at 00:00, 14 hours 12 minutes ago

Onco-Innovations Signs Agreement with Redwood AI to Advance Discovery and Evaluation of Its PNKP Inhibitor Technology
Published on 07/11/2025 at 23:41, 14 hours 31 minutes ago

Prince Silver Corp. Announces Closing of Stampede Acquisition, Issuance of Securities and Filing of Technical Report.

View all ACCESSWIRE

EQS Group

Published on 07/11/2025 at 20:44, 17 hours 28 minutes ago

Halfords Group PLC: Director/PDMR Shareholding
Published on 07/11/2025 at 20:21, 17 hours 50 minutes ago

EQS-Adhoc: Brenntag SE publishes preliminary results for the second quarter of 2025 and adjusts its guidance for the financial year 2025
Published on 07/11/2025 at 19:14, 18 hours 58 minutes ago

EQS-Adhoc: Drägerwerk AG & Co. KGaA: Preliminary figures H1 2025: Earnings positive but below prior year – net sales stable – significant increase in order intake – forecast confirmed
Published on 07/11/2025 at 18:42, 19 hours 30 minutes ago

Fuller, Smith & Turner PLC: Transaction in own shares
Published on 07/11/2025 at 18:12, 19 hours 59 minutes ago

Katjes International expects sale of 23% stake in CPK this year

Les Echos

Published on 07/11/2025 at 18:00, 20 hours 12 minutes ago

THERMADOR GROUPE : 2025 half year turnover
Published on 07/11/2025 at 18:00, 20 hours 12 minutes ago

THERMADOR GROUPE : chiffre d'affaires semestriels 2025
Published on 07/11/2025 at 17:45, 20 hours 27 minutes ago

EURAZEO ENTRE EN DISCUSSIONS EXCLUSIVES AVEC UNE HOLDING EUROPEENNE DU GROUPE FERRARA POUR LA CESSION DE SA PARTICIPATION DANS LE GROUPE CPK
Published on 07/11/2025 at 17:45, 20 hours 27 minutes ago

EURAZEO ENTERS INTO EXCLUSIVE DISCUSSIONS WITH A EUROPEAN HOLDING COMPANY OF FERRARA REGARDING THE SALE OF ITS STAKE IN THE CPK GROUP
Published on 07/11/2025 at 17:45, 20 hours 27 minutes ago

STEF : Droits de vote au 30-06-2025

View all LES ECHOS COMFI WIRE